Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5694/j.1326-5377.1984.tb108094.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.
BMC Pharmacol Toxicol
January 2025
Department of Community Medicine, Islamic International Medical College (IIMC), Riphah International University, Rawalpindi, Pakistan.
Objective: To determine the relative effectiveness of combination therapy of antidepressants with low-dose methylfolate versus antidepressant monotherapy in patients with depressive disorder.
Methods: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mirtazapine 15-30 mg, venlafaxine 75-150 mg, trazodone 50-100 mg, amitriptyline 25-75 mg, or clomipramine 25-75 mg orally daily for 4 weeks). The experimental group, Group B was additionally given a dose of methylfolate 800 µg daily for four weeks.
Boanmycin overcomes bortezomib resistance by inducing DNA damage and endoplasmic reticulum functional impairment in multiple myeloma.
Biol Direct
January 2025
Department of Hematology, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, 518172, China.
Background: Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled proliferation of plasma cells and is currently incurable. Despite advancements in therapeutic strategies, resistance to proteasome inhibitors, particularly bortezomib (BTZ), poses a substantial challenge to disease management. This study aimed to explore the efficacy of boanmycin, a novel antitumor antibiotic, in overcoming resistance to BTZ in MM.
View Article and Find Full Text PDFGastrointestinal absorption and its regulation of hawthorn leaves flavonoids.
Sci Rep
January 2025
School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, P.R. China.
Hawthorn leave flavonoids (HLF) are widely used as an herb or dietary supplements for cardio-cerebrovascular diseases. However, its gastrointestinal absorption behavior and mechanism have not been disclosed. In this study, gastrointestinal absorption and its regulation of 4''-O-glucosylvitexin (GLV), 2''-O-rhamnosylvitexin (RHV), vitexin (VIT), rutin (RUT) and hyperoside (HP) in HLF were investigated using in vitro, in situ and in vivo models.
View Article and Find Full Text PDFPersonalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma.
Breast Cancer Res Treat
December 2024
Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10/MedD5A, 20500, Turku, Finland.
Article Synopsis
- The study aims to improve predictions of disease outcomes for breast cancer patients undergoing neoadjuvant treatment (NAT) by analyzing clinical and histopathological data.
- Researchers evaluated a cohort of 257 Finnish breast cancer patients over 13 years, identifying significant prognostic factors and previously overlooked histological features that correlate with treatment response and survival.
- The findings suggest the importance of re-assessing biomarkers post-treatment and developing personalized surveillance and treatment strategies based on comprehensive evaluations of patient data and risk factors.
Editorial: The 2024 Revision of the Declaration of Helsinki and its Continued Role as a Code of Ethics to Guide Medical Research.
Med Sci Monit
December 2024
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA.
This year, 2024, marks the 60th anniversary of the Declaration of Helsinki, with the latest revision adopted by the World Medical Association (WMA) in October 2024. The 2024 Declaration of Helsinki is a statement document of ethical principles for research involving humans, human data, and human cells and tissues. Revising the 2013 Declaration of Helsinki document was undertaken over more than two years with international collaboration to enhance the inclusivity of medical research, protect the rights of research study participants, and address contemporary research challenges such as global health emergencies and data privacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!